Leslie Spry, MD
Nephrology · Lincoln, NENPI 1679522528
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $2,024 of the $3,186 with a category attached, or 63.5%. CSL Behring accounts for 68.7% of it on its own, with 26 other manufacturers making up the rest. 2024 is the largest year on record at $2,321, more than ten times the $100 reported in 2019.
Across 67 payments — averaging $47.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- CSL Behring$2K
- Aurinia Pharma U.S., Inc.$133
- Boehringer Ingelheim$92
- AstraZeneca$81
- Amgen$77
- Boston Scientific$64
- plus $548 from 21 others
Across 338 payments — averaging $2274.58 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Akebia Therapeutics Inc$210K
- Vertex$165K
- CSL Behring$158K
- Bayer$87K
- Astrazeneca UK Limited$56K
- Merck$33K
- plus $60K from 5 others
What the payments were for
- Travel & lodging$2,02464%
- Food & beverage$1,16336%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| CSL Behring | 10 | $2,190 |
| Aurinia Pharma U.S., Inc. | 8 | $133 |
| Boehringer Ingelheim | 5 | $92 |
| AstraZeneca | 5 | $81 |
| Amgen | 5 | $77 |
| Boston Scientific | 1 | $64 |
| Bayer | 4 | $55 |
| Baxter Healthcare | 1 | $44 |
| Fresenius USA Marketing, Inc. | 3 | $43 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $39 |
| Seagen Inc. | 2 | $34 |
| Travere Therapeutics, Inc. | 2 | $33 |
| Otsuka America Pharmaceutical, Inc. | 2 | $28 |
| GSK | 2 | $27 |
| Rockwell Medical, Inc. | 2 | $27 |
| Johnson & Johnson(2 entities) | 2 | $27 |
| Sanofi | 1 | $24 |
| Exelixis Inc. | 1 | $21 |
| Bard Peripheral Vascular, Inc. | 1 | $20 |
| Lexicon Pharmaceuticals, Inc. | 1 | $19 |
| Novartis | 1 | $17 |
| Eisai Inc. | 1 | $16 |
| Alnylam Pharmaceuticals Inc. | 1 | $16 |
| Novo Nordisk | 1 | $16 |
| AbbVie | 1 | $15 |
| Esperion Therapeutics, Inc. | 1 | $15 |
| Nxstage Medical, Inc. | 1 | $13 |
How this compares
$3,186 in reported general payments places this provider in the 75th percentile of 60 nephrology providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 33 | $31,066 |
| ProsolParenteral Amino Acid 20% No.1 | 52 | $20,825 |
| KerendiaFinerenone | 22 | $15,417 |
| JardianceEmpagliflozin | 18 | $12,759 |
| VascepaIcosapent Ethyl | 14 | $4,875 |
| Allopurinol | 57 | $896 |
| Torsemide | 22 | $655 |
| Calcium Acetate | 16 | $538 |
| Potassium Chloride | 21 | $529 |
| Lisinopril | 68 | $515 |
| Losartan Potassium | 46 | $474 |
| Bisoprolol Fumarate | 14 | $469 |
| Spironolactone | 28 | $463 |
| Amlodipine Besylate | 30 | $358 |
| Furosemide | 42 | $332 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $81 | $31,06633 claims |
| BayerKerendia | $55 | $15,41722 claims |
| Boehringer IngelheimJardiance | $92 | $12,75918 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 60 nephrology providers in Nebraska.
Other nephrology in Lincoln
- Michael AaronsonLincoln$498K
- Rachel BrockLincoln$87K
- Stephanie GawelLincoln$5K
- Matthew GlatharLincoln$1K
- Yifei ZhangLincoln$946
- Elizabeth CarthelLincoln$787
- Lisa ClevelandLincoln$758
- Son TranLincoln$468
- Sophia KnoellLincoln$390
- Nasimul GhaniLincoln$150
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.